These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 9926249)
21. Treatment of childhood Hodgkin's disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua. Baez F; Ocampo E; Conter V; Flores A; Gutierrez T; Malta A; Pacheco C; Palacios R; Biondi A; Riva L; Sala A; Silvestri D; Cavalli F; Sessa C; Casanova M; Masera G Ann Oncol; 1997 Mar; 8(3):247-50. PubMed ID: 9137793 [TBL] [Abstract][Full Text] [Related]
22. Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. Landman-Parker J; Pacquement H; Leblanc T; Habrand JL; Terrier-Lacombe MJ; Bertrand Y; Perel Y; Robert A; Coze C; Thuret I; Donadieu J; Schaison G; Leverger G; Lemerle J; Oberlin O J Clin Oncol; 2000 Apr; 18(7):1500-7. PubMed ID: 10735898 [TBL] [Abstract][Full Text] [Related]
23. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. Weiner MA; Leventhal B; Brecher ML; Marcus RB; Cantor A; Gieser PW; Ternberg JL; Behm FG; Wharam MD; Chauvenet AR J Clin Oncol; 1997 Aug; 15(8):2769-79. PubMed ID: 9256118 [TBL] [Abstract][Full Text] [Related]
24. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma. Bokemeyer C; Schmoll HJ; van Rhee J; Kuczyk M; Schuppert F; Poliwoda H Ann Hematol; 1994 Mar; 68(3):105-10. PubMed ID: 8167175 [TBL] [Abstract][Full Text] [Related]
25. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. Loeffler M; Diehl V; Pfreundschuh M; Rühl U; Hasenclever D; Nisters-Backes H; Sieber M; Tesch H; Franklin J; Geilen W; Bartels H; Cartoni C; Dölken G; Enzian J; Fuchs R; Gassmann W; Gerhartz H; Hagen-Aukamp U; Hiller E; Hinkelbein H; Hinterberger W; Kirchner H; Koch P; Krüger B; Schwarze EW J Clin Oncol; 1997 Jun; 15(6):2275-87. PubMed ID: 9196141 [TBL] [Abstract][Full Text] [Related]
26. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. Diehl V; Franklin J; Pfreundschuh M; Lathan B; Paulus U; Hasenclever D; Tesch H; Herrmann R; Dörken B; Müller-Hermelink HK; Dühmke E; Loeffler M; N Engl J Med; 2003 Jun; 348(24):2386-95. PubMed ID: 12802024 [TBL] [Abstract][Full Text] [Related]
27. [Significance of procarbazine in the chemotherapy of Hodgkin's disease--a report of the Cooperative Therapy Study DAL-HD-85]. Schellong G; Hörnig I; Brämswig J; Bökkerink JP; Steinhoff A; Ludwig R; Niethammer D; Reiter A; von Lengerke HJ; Heinecke H Klin Padiatr; 1988; 200(3):205-13. PubMed ID: 3062257 [TBL] [Abstract][Full Text] [Related]
28. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V; J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100 [TBL] [Abstract][Full Text] [Related]
29. BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group. Rüffer JU; Ballova V; Glossmann J; Sieber M; Franklin J; Nogova L; Diehl V; Josting A; Leuk Lymphoma; 2005 Nov; 46(11):1561-7. PubMed ID: 16236610 [TBL] [Abstract][Full Text] [Related]
30. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863 [TBL] [Abstract][Full Text] [Related]
31. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M; J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458 [TBL] [Abstract][Full Text] [Related]
32. [Hodgkin's lymphoma in adolescents: where to treat it--in an adult or pediatric institution?]. Müller J; Molnár Z; Illés A; Csóka M; Jakab Z; Deák B; Schneider T; Várady E; Rosta A; Simon Z; Keresztes K; Gergely L; Kovács G Orv Hetil; 2008 Nov; 149(47):2221-7. PubMed ID: 19004744 [TBL] [Abstract][Full Text] [Related]
33. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation. Chow LM; Nathan PC; Hodgson DC; Jenkin D; Weitzman S; Grant RM; Manson D; Bross A; Doyle JJ; Danjoux C; Greenberg ML J Clin Oncol; 2006 Dec; 24(36):5735-41. PubMed ID: 17179107 [TBL] [Abstract][Full Text] [Related]
34. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805 [TBL] [Abstract][Full Text] [Related]
35. Risk adapted combined modality treatment in children with Hodgkin's disease: NCI, Cairo. El-Badawy S; Aboulnaga S; Abou Gabal A; Mokhless A; Zamzam M; Sidhom I; Ebeid E; Hussein H J Egypt Natl Canc Inst; 2008 Jun; 20(2):99-110. PubMed ID: 20029465 [TBL] [Abstract][Full Text] [Related]
36. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience. Hunger SP; Link MP; Donaldson SS J Clin Oncol; 1994 Oct; 12(10):2160-6. PubMed ID: 7523608 [TBL] [Abstract][Full Text] [Related]
37. Hodgkin disease in children: results of a prospective randomized trial in a single institution in Argentina. Sackmann-Muriel F; Zubizarreta P; Gallo G; Scopinaro M; Alderete D; Alfaro E; Casak S; Chantada G; Felice MS; Quinteros R Med Pediatr Oncol; 1997 Dec; 29(6):544-52. PubMed ID: 9324342 [TBL] [Abstract][Full Text] [Related]
38. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group. Eich HT; Staar S; Gossmann A; Hansemann K; Skripnitchenko R; Kocher M; Semrau R; Engert A; Josting A; Franklin J; Krug B; Diehl V; Müller RP; Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1121-7. PubMed ID: 15001253 [TBL] [Abstract][Full Text] [Related]
39. [Therapy studies of the German Hodgkin's Study Group. Intermediate results of the study protocols HD1, HD2, and HD3]. Diehl V; Pfreundschuh M; Löffler M; Smith K; Rühl U; Georgii A; Hiller E; Gerhartz H Onkologie; 1987 Apr; 10(2):62-6. PubMed ID: 2438613 [TBL] [Abstract][Full Text] [Related]
40. [Reducing radiation dosage to 20-30 Gy in combined chemo-/radiotherapy of Hodgkin's disease in childhood. A report of the cooperative DAL-HD-87 therapy study]. Schellong G; Hörnig-Franz I; Rath B; Ritter J; Riepenhausen M; Kabisch H; Goldschmitt-Wuttge B; Schmidt P; Niethammer D; Gaedicke G Klin Padiatr; 1994; 206(4):253-62. PubMed ID: 7967421 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]